Trial Profile
A double-blind, randomized, placebo-controlled Phase I single ascending dose study of C21
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2018
Price :
$35
*
At a glance
- Drugs C-21 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- 12 Jul 2018 New trial record
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society